MARKET

MTEM

MTEM

Molecular US
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.52
+0.38
+3.41%
After Hours: 11.52 0 0.00% 16:00 08/07 EDT
OPEN
10.53
PREV CLOSE
11.14
HIGH
11.88
LOW
9.87
VOLUME
469.48K
TURNOVER
--
52 WEEK HIGH
19.12
52 WEEK LOW
4.510
MARKET CAP
526.55M
P/E (TTM)
-5.3410
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MTEM stock price target is 22.00 with a high estimate of 25.00 and a low estimate of 20.00.

EPS

MTEM News

More
Molecular Templates EPS misses by $0.32, beats on revenue
Molecular Templates (NASDAQ:MTEM): Q2 GAAP EPS of -$0.68 misses by $0.32. Revenue of $6.91M (+26.8% Y/Y) beats by $1.89M. Press Release
seekingalpha · 2d ago
Molecular Templates, Inc. Reports Second Quarter 2020 Financial Results
AUSTIN, Texas, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic ther
GlobeNewswire · 2d ago
Molecular Templates raises $43M
Molecular Templates (NASDAQ:MTEM) has raised ~$43M through its At-the-Market facility, with participation from Consonance Capital Management. The Company s
seekingalpha · 07/21 02:05
Molecular Templates, Inc. Raises $43M In Gross Proceeds Through Its At-The-Market Facility
AUSTIN, Texas, July 20, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, &ldquo, Molecular Templates, &rdquo, &ldquo, MTEM&rdquo, or the &ldquo, Company&rdquo, )), a clinical-stage biopharmaceutical
Benzinga · 07/20 20:32
Molecular Templates (MTEM) Investor Presentation - Slideshow
Seeking Alpha - Article · 06/26 17:36
Is Molecular Templates, Inc. (MTEM) A Good Stock To Buy?
Insider Monkey · 06/24 21:04
Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2020 Highlight Evolution of ETB Platform
Update Provided Phase I Study of MT-5111 in HER2-positive Cancers Conference Call and Webcast to Discuss AACR Posters on June 25th at 10:30am Eastern Time AUSTIN, Texas, June.
GlobeNewswire · 06/22 11:30
Molecular Templates: Updates To Thesis, Pursuing Validated Targets With Unique MOA
Seeking Alpha - Article · 06/10 07:07

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About MTEM

Molecular Templates, Inc., formerly Threshold Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. The Company also focused on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies (ETBs). The Company is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. The Company’s lead drug candidate MT-3724 is an is an immunotoxin that targets the CD20 cell surface antigen present in a variety of lymphomas and leukemias.
More

Webull offers kinds of Molecular Templates Inc stock information, including NASDAQ:MTEM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTEM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MTEM stock methods without spending real money on the virtual paper trading platform.